|Bioavailability||25–30% (rubitecan and 9-AC; in dogs)|
|Protein binding||97% (rubitecan), 65% (9-AC)|
|Biological half-life||15–18 hours (rubitecan), 18–22 hours (9-AC)|
|Excretion||Bile and feces (major proportion), urine (the minor one)|
|Chemical and physical data|
|Molar mass||393.349 g/mol|
|3D model (Jmol)|
|(what is this?)|
On January 2005, Supergen withdrew the NDA for rubitecan, based on feedback indicating that the current data package would not be sufficient to gain US approval, and on January 2006, the Marketing Authorization Application (MAA) filed with the European Medicines Agency (EMA) was also withdrawn.
- "Withdrawal Assessment Report for Orathecin (rubitecan). Applicant: EuroGen Pharmaceuticals, Ltd." (PDF). European Medicines Agency. 30 November 2007. pp. 4–8. Retrieved 15 July 2016.
- "Drugs.com, SuperGen completes submission of New Drug Application (NDA) for Orathecin as an oral treatment for pancreatic cancer". Retrieved 2008-03-25.
- "Drugs.com, SuperGen’s New Drug Application for Orathecin (rubitecan) capsules accepted by FDA for filing". Retrieved 2008-03-25.
- "Drugs.com, SuperGen Announces Withdrawal of Orathecin NDA". Retrieved 2008-03-25.
- "Press release from the EMEA website regarding withdrawal of Orathecin MAA" (PDF). Retrieved 2008-03-25.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|